NUTRACEUTICAL CO-CRYSTAL COMPOSITIONS
First Claim
1. A composition comprising a co-crystal of a nutraceutical and a co-crystal former, the co-crystal with or without impurities wherein(i) the nutraceutical and the co-crystal former are hydrogen bonded to each other,(ii) the nutraceutical is selected from the group consisting of vitamin B2 (riboflavin), glucosamine HCl, chlorogenic acid, lipoic acid, catechin hydrate, creatine, acetyl-L-carnitine HCl, vitamin B6, pyridoxine, caffeic acid, naringenin, vitamin B1 (thiamine HCl), baicalein, luteolin, hesperedin, rosmarinic acid, epicatechin gallate, epigallocatechin, vitamin B9 (folic), genistein, methylvanillin, ethylvanillin, silibinin, diadzein, melatonin, rutin hydrate, vitamin A, retinol, vitamin D2 (ergocalciferol), vitamin E (tocopherol), diosmin, menadione (K3), vitamin D3 (caholecalciferol), phloretin, indole-3-carbinol, fisetin, glycitein, chrysin, gallocatechin, vitamin B4 (adenine), vitamin B5 (pantothenic acid), vitamin B7 (biotin), theobromine, quercetin, ferulic acid, ellagic acid, hesperitin, and protocatechuic acid, and(iii) a co-crystal former selected from the group consisting of pharmaceutically acceptable carbohydrates, amines, amides, sulfonamides, carboxylic acids, sulfonic acids, phenols, polyphenols, aromatic heterocycles, xanthines and alcohols.
1 Assignment
0 Petitions
Accused Products
Abstract
Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.
81 Citations
69 Claims
-
1. A composition comprising a co-crystal of a nutraceutical and a co-crystal former, the co-crystal with or without impurities wherein
(i) the nutraceutical and the co-crystal former are hydrogen bonded to each other, (ii) the nutraceutical is selected from the group consisting of vitamin B2 (riboflavin), glucosamine HCl, chlorogenic acid, lipoic acid, catechin hydrate, creatine, acetyl-L-carnitine HCl, vitamin B6, pyridoxine, caffeic acid, naringenin, vitamin B1 (thiamine HCl), baicalein, luteolin, hesperedin, rosmarinic acid, epicatechin gallate, epigallocatechin, vitamin B9 (folic), genistein, methylvanillin, ethylvanillin, silibinin, diadzein, melatonin, rutin hydrate, vitamin A, retinol, vitamin D2 (ergocalciferol), vitamin E (tocopherol), diosmin, menadione (K3), vitamin D3 (caholecalciferol), phloretin, indole-3-carbinol, fisetin, glycitein, chrysin, gallocatechin, vitamin B4 (adenine), vitamin B5 (pantothenic acid), vitamin B7 (biotin), theobromine, quercetin, ferulic acid, ellagic acid, hesperitin, and protocatechuic acid, and (iii) a co-crystal former selected from the group consisting of pharmaceutically acceptable carbohydrates, amines, amides, sulfonamides, carboxylic acids, sulfonic acids, phenols, polyphenols, aromatic heterocycles, xanthines and alcohols.
- 8. A co-crystal composition comprising EGCG and a co-crystal former wherein EGCG and the co-crystal former are hydrogen bonded to each other, the co-crystal being with or without impurities.
- 12. A co-crystal comprising at least one nutraceutical compound and L-ascorbic acid wherein the nutraceutical compound and L-ascorbic acid are hydrogen bonded.
-
16. A co-crystal comprising:
- a nutraceutical and a co-crystal former, wherein the nutraceutical is a flavonoid and the co-crystal former is a xanthine.
- View Dependent Claims (17)
-
18. A co-crystal, comprising:
- a nutraceutical and a co-crystal former, wherein the nutraceutical is epigallocatechin-3-gallate, quercetin, or hesperitin, and the co-crystal former is caffeine, theobromine, or theophylline
-
19. A process for the preparation of a nutraceutical co-crystal, the process comprising combining at least one nutraceutical and at least one co-crystal former and inducing the nutraceutical(s) and the co-crystal former(s) to hydrogen bond with each other wherein:
-
(i) the nutraceutical is selected from the group consisting of vitamin B2 (riboflavin), glucosamine HCl, chlorogenic acid, lipoic acid, catechin hydrate, creatine, acetyl-L-carnitine HCl, vitamin B6, pyridoxine, caffeic acid, naringenin, vitamin B1 (thiamine HCl), baicalein, luteolin, hesperedin, rosmarinic acid, epicatechin gallate, epigallocatechin, vitamin B9 (folic), genistein, methylvanillin, ethylvanillin, silibinin, diadzein, melatonin, rutin hydrate, vitamin A, retinol, vitamin D2 (ergocalciferol), vitamin E (tocopherol), diosmin, menadione (K3), vitamin D3 (caholecalciferol), phloretin, indole-3-carbinol, fisetin, glycitein, chrysin, gallocatechin, vitamin B4 (adenine), vitamin B5 (pantothenic acid), vitamin B7 (biotin), theobromine, quercetin, ferulic acid, ellagic acid, hesperitin, and protocatechuic acid, and (ii) a co-crystal former selected from the group consisting of pharmaceutically acceptable carbohydrates, amines, amides, sulfonamides, carboxylic acids, sulfonic acids, phenols, polyphenols, aromatic heterocycles, xanthines and alcohols. - View Dependent Claims (20, 21, 22, 23, 24, 25)
-
- 26. A process for the preparation of a nutraceutical co-crystal, the process comprising combining at least one nutraceutical and at least one co-crystal former and inducing the nutraceutical(s) and the co-crystal former(s) to hydrogen bond with each other wherein the nutraceutical comprises EGCG.
- 30. A process for the preparation of a nutraceutical co-crystal, the process comprising combining at least one nutraceutical compound and L-ascorbic acid and inducing the nutraceutical compound(s) and L-ascorbic acid to hydrogen bond with each other.
- 34. A process for the preparation of a nutraceutical co-crystal comprising a flavonoid and a xanthine, the process comprising combining the flavonoid and the xanthine and inducing the flavonoid and the xanthine to hydrogen bond with each other.
-
37. A process for improving animal health or nutrition, the process comprising administering to the animal a composition comprising a nutraceutical co-crystal wherein
(i) the nutraceutical co-crystal comprises a nutraceutical and a co-crystal former hydrogen bonded to each other, the nutraceutical co-crystal with or without impurities (ii) the nutraceutical is selected from the group consisting of vitamin B2 (riboflavin), glucosamine HCl, chlorogenic acid, lipoic acid, catechin hydrate, creatine, acetyl-L-carnitine HCl, vitamin B6, pyridoxine, caffeic acid, naringenin, vitamin B1 (thiamine HCl), baicalein, luteolin, hesperedin, rosmarinic acid, epicatechin gallate, epigallocatechin, vitamin B9 (folic), genistein, methylvanillin, ethylvanillin, silibinin, diadzein, melatonin, rutin hydrate, vitamin A, retinol, vitamin D2 (ergocalciferol), vitamin E (tocopherol), diosmin, menadione (K3), vitamin D3 (caholecalciferol), phloretin, indole-3-carbinol, fisetin, glycitein, chrysin, gallocatechin, vitamin B4 (adenine), vitamin B5 (pantothenic acid), vitamin B7 (biotin), theobromine, quercetin, ferulic acid, ellagic acid, hesperitin, and protocatechuic acid, and (iii) the co-crystal former selected from the group consisting of pharmaceutically acceptable carbohydrates, amines, amides, sulfonamides, carboxylic acids, sulfonic acids, phenols, polyphenols, aromatic heterocycles, xanthines and alcohols.form of epigallocatechin-3-gallate to a person or animal having or predisposed to having a condition resulting from oxidative stress.
- 44. A process for improving animal health or nutrition, the process comprising administering to the animal a composition comprising a nutraceutical co-crystal comprising EGCG and a co-crystal former.
- 48. A process for improving animal health or nutrition, the process comprising administering to the animal a composition comprising a nutraceutical co-crystal comprising at least one nutraceutical compound and L-ascorbic acid.
- 52. A process for improving animal health or nutrition, the process comprising administering to the animal a composition comprising a nutraceutical co-crystal comprising a flavonoid and a xanthine.
-
55. (canceled)
- 61. A pharmaceutical composition comprising a co-crystal comprising at least one nutraceutical compound and L-ascorbic acid wherein the nutraceutical compound and L-ascorbic acid are hydrogen bonded.
-
66. (canceled)
-
67. A method of making a co-crystal, the method comprising:
- combining a nutraceutical compound and a first solvent to form a nutraceutical admixture;
combining L-ascorbic acid and a second solvent to form an L-ascorbic acid admixture;
combining the nutraceutical admixture and the L-ascorbic acid admixture under crystallization conditions to form a co-crystal in a solid phase, the co-crystal comprising the nutraceutical and L-ascorbic acid wherein the nutraceutical compound and L-ascorbic acid are hydrogen bonded; and
optionally isolating the co-crystal. - View Dependent Claims (68)
- combining a nutraceutical compound and a first solvent to form a nutraceutical admixture;
-
69-81. -81. (canceled)
Specification